SCHEMBL1926737

SCHEMBL1926737

Brc1ccc(-c2cccc(Br)c2)nc1.Brc1ccc(-c2cccc(Br)c2)nc1.Brc1ccc(-c2cccc(Br)c2)nc1.[Ir]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.51
METAP2 P50579 1/20 0.51
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HK1 P19367 1/20 0.46
HKDC1 Q2TB90 1/20 0.46
GABRG2 P18507 3/20 0.45
GABRB3 P28472 3/20 0.45
GABRA5 P31644 3/20 0.45
GABRA3 P34903 3/20 0.45
GABRA1 P14867 2/20 0.45
BIRC5 O15392 1/20 0.45
HSD17B1 P14061 2/20 0.44
HSD17B2 P37059 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 2/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27614819 1.00 IDO1 (0.51) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL1925054 0.98 IDO1 (0.53) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL13917369 0.90 HSD17B1 (0.48) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL17027901 0.84 IDO1 (0.58) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL2482041 0.83 HSD17B1 (0.47) IDO1METAP2RAB9AALDH1A1GABRG2
SCHEMBL15747739 0.81 HPGDS (0.56) IDO1MAPTHSD17B1HSD17B2MEN1
SCHEMBL2482706 0.81 CYP3A4 (0.54) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL969090 0.81 MAP4K4 (0.50) METAP2RAB9AALDH1A1MAPTHPGD
SCHEMBL22660886 0.81 HSD17B1 (0.54) IDO1METAP2RAB9AALDH1A1MAPT
SCHEMBL15014085 0.81 KDM1A (0.54) IDO1METAP2ALDH1A1HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536333-B2 Neutral metallic dendrimer complexes ISIS INNOVATION LIMITED (GB) 2013-09-17 US disclosed
US-20110127496-A1 Neutral Metallic Dendrimer Complexes CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2011-06-02 US disclosed
US-7799917-B2 Neutral metallic dendrimer complexes ISIS INNOVATION LIMTED (GB) 2010-09-21 US disclosed
EP-1532158-B1 NEUTRAL METALLIC DENDRIMER COMPLEXES ISIS INNOVATION (GB) 2008-10-15 EP disclosed
US-20060119254-A1 Neutral metallic dendrimer complexes CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060119254-A1 Neutral metallic dendrimer complexes ZYX, MLX, ZFX IDO1 1602/4885METAP2 2375/4885RAB9A 1073/4885
US-20110127496-A1 Neutral Metallic Dendrimer Complexes ZYX, MLX, ZFX IDO1 1602/4885METAP2 2375/4885RAB9A 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.